Congratulations to Dr. Stefano Menegatti and Carol Hall in receiving funding for their joint proposal in designing and testing of Fab-binding peptides!
Category Archives: NC State
$1.1M NIIMBL (NIST) Research Grant
NC State receives $1.1M NIIMBL (NIST) funding to innovate downstream bioprocessing
Dr. Stefano Menegatti will lead the NCSU team in a collaborative, multi-institutional project funded by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The NCSU team comprises researchers in Chemical Engineering, BTEC, and Biochemistry. The project, entitled “Identification, Characterization and Removal of Host-Cell Proteins (HCP) in Chinese Hamster Ovary (CHO) Monoclonal Antibody Biomanufacturing Processes”, focuses on developing novel, continuous methods for the purification of therapeutic antibodies, and has received a total funding of about $2.5M, of which $1.1M is awarded to NCSU. The research effort will involve three universities, University of Delaware (Leader institution, PI: Abraham Lenhoff), NC State University (PI: Stefano Menegatti) and Rensselaer Polytechnic Institute (PI: Steven Cramer), and two major biopharmaceutical companies, Genentech and Merck.
GlaxoSmithKline
Congratulations to Annalisa for getting a job at GSK! Her hard work and determination has got her this great opportunity and we are all very proud of her!
ANNALISA’S POTLUCK
Farewell party for our international Master student from Italy! It’s been a great six months!
Welcome New Graduate Students
The Menegatti Lab has taken 3 new graduate students into its ranks this semester. They’ll all be working on diverse projects in separations and drug delivery using hot new materials and recently discovered peptide sequences.
So say hello to Raphael Prodromou, Kevin Day, and Srivatsan Ramesh (pictured left to right).
John Schneible Wins GAANN Fellowship
John Schneible has won the GAANN Fellowship for graduate students in biotechnology who have demonstrated interest and commitment towards furthering higher education through research. He was nominated and competed against other students to win the award and become a GANN Fellow.
The GAANN Fellowship is sponsored by the Department of Education, and the Biotechnology Center of North Carolina implements the molecular biotechnology section of the fellowhip. The GAANN committee seeks to foster the next generation of scientists into better researchers, teachers, and mentors. We’re already sure John’s well on his way to that goal!
Congratulations to John Schneible, GAANN Fellow!
Congratulations to John Schneible!
Congratulations to John Schneible, who passed his preliminary exam. We all look forward to his continued research on drug delivery and have every confidence that ‘synergy’ is happening!
Best wishes to John, and best of luck on his future work!
Congratulations to Kaitlyn Bacon!
Congratulations to Kaitlyn Bacon, who passed her preliminary exam. She is now a full PhD candidate and one big step closer to getting her degree. Her work will be featured here as it continues to be developed.
Best wishes to Kaitlyn, and good luck on her continued research!
Biopep/Sensus Team Members Compete in Eindhoven!
Sensus, an international, undergraduate competition to sense biomolecules, held its annual contest on September 8th and 9th. The SenseNC team had three representatives that also perform research in the BioPep labs who went to the Netherlands to represent the team. From left to right, Brendan Turner, Alice DiFazio, and Calvin Shanahan all had a great time and showed off the work of the team.
Also cool, the SenseNC team was the only – and the first – team from the US to compete, and thus also the first team to place in several categories! Next year we’ll be even better!
Congrats to SenseNC, the SensUs competition, and all the potential patients who may be helped through the technologies developed.
New Paper from Dr. Menegatti
Dr. Menegatti’s work in Santa Barbara continues to have far reaching effects, as seen in the recent publication “A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer” in the Journal of Controlled Release. Some of the ideas presented in this paper continue to inform our work and push the boundaries of drug delivery.
Congrats to Dr. Menegatti!